Medication info
H-Prasole Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

H-Prasole Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›21.69mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
Pale pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP packaging x 2)
Approval status
Active

MFDS item code 201501774 · Approved 2015.03.31 · Insurance code 642003540

Summary

Main use
Treatment of gastroesophageal reflux, gastrointestinal disorders (ulcers, Helicobacter pylori infection, etc.), and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use is not recommended for controlling recurrent symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg, twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective COX-2, selective COX-2) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials exceeding 4 weeks have not been conducted. 4) Patients requiring continuous treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers. 4. Renal impairment No dosage adjustment is necessary. Use with caution, as there is limited experience with administration to patients with severe renal impairment. 5. Hepatic impairment No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dosage adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use is not recommended for controlling recurrent symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age There is no experience with administering this medicine to children under 12 years of age.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of gastroesophageal reflux, gastrointestinal disorders (ulcers, Helicobacter pylori infection, etc.), and Zollinger-Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • symptoms of gastroesophageal reflux disease without esophagitis
  • duodenal ulcers positive for Helicobacter pylori
  • peptic ulcers positive for Helicobacter pylori
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers associated with nonsteroidal anti-inflammatory drugs
  • duodenal ulcers associated with nonsteroidal anti-inflammatory drugs
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease, especially for the long-term maintenance therapy to prevent the recurrence of erosive reflux esophagitis. It is also effective in alleviating symptoms of gastroesophageal reflux disease without esophagitis. It aids in the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers in conjunction with antibiotics for the eradication of Helicobacter pylori. It is also utilized as a short-term therapy for the treatment of upper gastrointestinal symptoms, especially pain and discomfort, associated with nonsteroidal anti-inflammatory drugs. Continuous use in patients on nonsteroidal anti-inflammatory drugs is for the treatment of gastric ulcers and the prevention of gastric and duodenal ulcers. Finally, this medication is effective in the treatment of Zollinger-Ellison syndrome and as maintenance therapy to prevent rebleeding of gastric or duodenal ulcers.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use is not recommended for controlling recurrent symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg, twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective COX-2, selective COX-2) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials exceeding 4 weeks have not been conducted. 4) Patients requiring continuous treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with the use of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous treatment to prevent rebleeding from gastric or duodenal ulcers. 4. Renal impairment No dosage adjustment is necessary. Use with caution, as there is limited experience with administration to patients with severe renal impairment. 5. Hepatic impairment No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dosage adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use is not recommended for controlling recurrent symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age There is no experience with administering this medicine to children under 12 years of age.

Precautions

This medication should not be administered to patients who have allergies to specific components or benzimidazole derivatives. Additionally, patients with allergies to penicillin and macrolide antibiotics should use caution. Patients taking specific heart-related medications or antivirals and those with a history of myocardial infarction or who are breastfeeding should avoid using this medication. Patients who are allergic or hypersensitive to Yellow No. 5 should use this medication cautiously. This medication can cause various side effects, commonly including headache, abdominal pain, diarrhea, etc. Rarely, serious side effects may occur, such as blood cell reduction, hypersensitivity reactions, hypomagnesemia, mental confusion, liver dysfunction, skin rashes, and others, so if any unusual symptoms appear, immediate consultation with medical personnel is advised. Regular checks are needed for long-term usage, especially if taken for more than one year, paying attention to magnesium levels and the risk of fractures. This medication reduces stomach acid and can increase bacterial growth in the stomach, thus increasing the risk of diarrhea and infections. There are many drug interactions, therefore when combined with specific drugs, follow the directives of medical personnel, and it should not be co-administered with some medications. During pregnancy, safety data is limited, so a consultation with a doctor is required before use, and it is recommended not to use while breastfeeding. In the case of overdose, there is no specific antidote, thus treatment should be administered as per symptoms, and it should be stored out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distention, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, eosinophilia, drug reaction with systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, hyperhidrosis, Clostridium difficile-associated diarrhea, abdominal distention, allergic reaction, back pain, chest pain, substernal chest pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, general edema, leg edema, lethargy, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, goiter, irritable bowel syndrome, worsening constipation, dyspepsia, dysphagia, gastrointestinal motility disorder, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorder, pharyngeal disorder, rectal disorder, gastrointestinal symptoms, increased serum gastrin, tongue disorder, tongue swelling, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, nasal bleeding, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, worsening arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, polymyalgia rheumatica, arthralgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, muscle hypertonicity, anxiety, sensory loss, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disorder, tremor, dizziness, visual field defect, paresthesia, drowsiness, dysmenorrhea, menstrual disorder, vaginitis, worsening asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, hyperhidrosis, otitis media, altered smell, taste loss, taste alteration, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stenosis, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp, nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric antrum polyp, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP packaging x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.